CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 34 enrolled
Drug / intervention
VTAMA® (tapinarof) Cream 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05680740
NCT05680740Phase 4Completed
CompareCT.gov

A Phase 4, Open-label, Study to Investigate the Efficacy and Safety of VTAMA® (Tapinarof) Cream 1% in the Treatment of Plaque Psoriasis in Intertriginous Areas

Organon and Co·interventional·Posted Jan 11, 2023·Updated Jun 12, 2025

In Brief

A Phase 4 clinical trial evaluating VTAMA® (tapinarof) Cream 1% for Psoriasis. Completed, enrolled 34 participants across 7 sites.

Detailed Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedJan 11, 2023
Enrollment StartDec 27, 2022
Primary CompletionMay 18, 2023
Study CompletionMay 25, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 3.5 years ago

Interventions

VTAMA® (tapinarof) Cream 1%drug

VTAMA® (tapinarof) Cream 1% applied topically once daily